- Home
- CHI vs LXRX Comparison
CHI vs LXRX Comparison
Compare CHI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | LXRX |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 996.7M |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CHI | LXRX |
|---|---|---|
| Price | $12.21 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 130.2K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $10.26 | $1.06 |
| 52 Week High | $13.50 | $2.68 |
Technical Indicators
Market Signals| Indicator | CHI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 37.77 |
| Support Level | $11.97 | $2.01 |
| Resistance Level | $12.13 | $2.49 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 10.18 | 31.94 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.